• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Stories

Elsemani Widaa

Home > Stories

Elsemani Widaa

Dr Elsemani Widaa
14 Jan 2016

Sudan

Dr Elsemani Widaa is a surgeon from the Mycetoma Research Centre, Sudan, which is the country’s treatment reference centre for patients’ suffering from the disease. He has worked at the Centre for over two years, and even in this short period of time, he has seen and treated hundreds of patients. The challenges that doctors face in treating mycetoma are many, the most serious of which problem is the fact that the only available drug for treating the fungal form of the disease (eumycetoma) is toxic and ultimately ineffective, but currently, it is all there is.

‘Every time I give a patient the treatment, in my mind I know that there is a high chance it might not work. I know they will keep on coming for many years but might never fully recover. This is really sad’, explains Dr Widaa.

The Mycetoma Research Centre will be the site for a clinical trial by Drugs for Neglected Diseases initiative in collaboration with Eisai, a Japanese pharmaceutical company, to test a drug called fosravuconazole. The trial aims to begin in early 2016.

Thinking of the prospects of a better treatment for his patients, Dr Widaa considers his patients. ‘I would like to be able to look into the eyes of my mycetoma patient and know that there is hope that they could actually get better’, he concludes.

Mycetoma Sudan

Read, watch, share

Loading...
Statements
19 May 2026

DNDi interventions at the 79th World Health Assembly

Dr Sergio Sosa-Estani
Statements
15 May 2026

DNDi statement on hantavirus outbreak: ‘Investment in pandemic preparedness efforts remains insufficient.’

Statements
13 May 2026

DNDi’s briefing note for 79th World Health Assembly

Close up of legs with sandals on a dry soil
Press releases
12 May 2026

DNDi welcomes GHIT support for global evaluation and registration of fosravuconazole for eumycetoma, in collaboration with Eisai

Press releases
27 Apr 2026

Thailand registers ravidasvir, a simple-to-use and effective antiviral for hepatitis C, expanding treatment options for Thai patients

Stories

Lab lessons that matter: Pharmacy students help bridge the gap in research for neglected diseases

News
31 Mar 2026

DNDi is looking for a Board Treasurer to join its Board of Directors

Title copy on white and orange background, picture of Fr Robinson on the right hand
Videos
26 Mar 2026

Manufacturing medicines for NTDs, with Dr Stephen Robinson

VIEW ALL

Help neglected patients

To date, we have delivered fourteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Youtube X-twitter Tiktok Facebook-f
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films, and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license